# K090725: Oculus Microcyn Wound Gel

- Pathway: 510(k) (Traditional)
- Applicant: Oculus Innovative Sciences, Inc.
- Decided: May 20, 2009 after 62 days
- Product code: FRO (Dressing, Wound, Drug)
- Device class: U
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 3 generations back to K830708 (1983). 6 ancestors in all.
56 later devices descend from it; 4 cite it directly.
0 of 63 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K020325: L.a.M. Ipm Wound Gel, L.A.M. Pharmaceutical, Corp. (2002) Summary page 1.

## Most influential descendants
- K100918: Vashe Wound Therapy System Model: 9000-0014 (2010), 31 descendants of its own
- K123072: Vashe Wound Therapy Solution (2013), 25 descendants of its own
- K093585: Microcyn Skin and Wound Hydrogel (2010), 25 descendants of its own
- K093697: Vashe Wound Therapy Solution (2010), 20 descendants of its own
- K102945: Pediacyn Atopic Dermatitis Hydrogel (2011), 17 descendants of its own

## Indications for use
OTC: Oculus Microcyn Skin and Wound Gel is intended for OTC use for the management of minor skin abrasions, lacerations, cuts and intact skin. Professional Use: Under the supervision of a health care professional, Oculus Puracyn Wound Gel is intended for the management of exuding wounds such as leg ulcers, pressure ulcer, diabetic ulcers and for the management of mechanically or surgically debrided wounds.

Source page: https://510kreport.com/device/K090725
Methodology: https://510kreport.com/methodology